Ubs Asset Management Americas Inc Rocket Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $477 Billion
- Q2 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 286,312 shares of RCKT stock, worth $910,472. This represents 0.0% of its overall portfolio holdings.
Number of Shares
286,312
Previous 184,692
55.02%
Holding current value
$910,472
Previous $1.23 Million
43.05%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding RCKT
# of Institutions
221Shares Held
98.4MCall Options Held
611KPut Options Held
474K-
Rtw Investments, LP New York, NY17.7MShares$56.2 Million0.67% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx8.36MShares$26.6 Million0.35% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$19.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.12MShares$19.5 Million0.0% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.82MShares$15.3 Million0.17% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $241M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...